Phase 1/2/3

With FDA clearance, Gain Therapeutics' GT-02287, an AI-discovered drug, advances to Phase 2, offering a new hope to modify Parkinson's, not just its symptoms.

Artelo Biosciences advances a novel non-opioid painkiller, using AI to map its effects and potentially revolutionize how we treat chronic pain.

Evommune halts a key drug trial for chronic hives but leans on a strong cash position and a diversified pipeline to navigate the setback.

With its fibromyalgia drug now on the market, Tonix is expanding its use to MDD, targeting disturbed sleep in a novel approach for millions of patients.

Early results for AB Science's AB8939 show a 67% response rate in high-risk AML patients, offering a potential breakthrough where other treatments fail.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

ProQR Therapeutics secures a crucial $59.2M, extending its runway and gaining a powerful endorsement from partner Eli Lilly for its Axiomer RNA editing platform.

ProQR's Axiomer platform achieves its first human validation, showing promise for rare pediatric liver diseases and signaling a major step for RNA editing.

A small biotech reports its novel curcumin gel eases sickle cell pain. But its strategy of pre-approval access via pharmacies is a high-stakes economic gamble.

A novel drug aims to reverse myelin damage in MS, a feat no current therapy can achieve. But with a recent FDA hold, is Quantum BioPharma's vision a breakthrough or a mirage?

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Kalaris Therapeutics, backed by VEGF pioneer Dr. Napoleone Ferrara, presents early data on its next-gen eye drug. Can TH103's novel science overcome recent development hurdles?

Amylyx reveals positive initial safety data for its new ALS drug, AMX0114, a critical step as the firm aims to rebuild after the Relyvrio withdrawal.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

With FDA clearance for its first-in-class remyelination drug, Scottish biotech Pheno Therapeutics is moving beyond inflammation to repair neurological damage.

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

Biotech firm ProJenX reports its novel ALS drug, prosetin, is safe and hits key targets in early trials, offering a new beacon of hope for the disease.

Pasithea Therapeutics is expanding its NF1 trial for PAS-004, a move that signals a deeper strategic commitment to outmaneuvering competitors and meeting a critical unmet medical need.